Tag Archives: celiac disease

← Older posts

Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More

Clinical trials have historically hewn to a rigid format. A trial is designed, conducted according to that design, and then results are analyzed. Making changes in the midst of the study was a no-no. In recent years, regulators have showed openness to clinical trial designs intended to make drug testing more efficient. We’ll get to […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More

Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel

There was plenty at stake in this week’s midterm elections, and not just in terms of political wins and losses. With congress now divided—Democrats took back control of the House and Republicans extended their majority in the Senate—the implications are significant for U.S. healthcare. Just a day after the results, for instance, Senate Majority Leader […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel

Amgen Picks Provention to Continue Development of Celiac Disease Drug

For the second time in three years, Amgen is turning to a smaller biotech to continue clinical development of an experimental celiac disease drug that was developed in its labs. Under a deal announced Monday, Provention Bio (NASDAQ: PRVB) will license the Amgen (NASDAQ: AMGN) drug, AMG714, and test it in a mid-stage study. Amgen […]

Posted in National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , | Comments Off on Amgen Picks Provention to Continue Development of Celiac Disease Drug

ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest

ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge of its most substantial clinical test to date, the company has also come up with its biggest round of funding from some well-known backers. Arch Venture Partners has joined previous ImmusanT backer Vatera Healthcare Partners […]

Posted in Boston, Boston blog main, Boston top stories, National blog main | Tagged , , , , , , , , , , , , , , | Comments Off on ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest

PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda

[Corrected 1/5/17, 8:07 am to show company was spun out of UW two months ago.] A San Diego-based startup spun out from the University of Washington just two months ago is today announcing a $35 million deal with Takeda, Japan’s biggest pharmaceutical. PvP Biologics was founded to advance KumaMax, a synthetic enzyme (depicted in the […]

Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on PvP Biologics Raises $35M in a Lab-to-Pharma Deal with Takeda

Retooled Selecta Bio Takes Crossover Cash to IPO Queue

Selecta Biosciences became a candidate to go public when a group of crossover investors—institutions that back both public and private companies—piled $38 million into the company in September. Nine months later, the Watertown, MA-based company is ready to take the leap. Selecta filed papers with the Securities and Exchange Commission late Tuesday outlining plans for […]

Posted in Boston, Boston blog main, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Retooled Selecta Bio Takes Crossover Cash to IPO Queue

Selecta, Eyeing IPO, Brings Sanofi, Crossovers Aboard For $38M Round

Crossover investors—institutions that back both public and private companies—have been piling money into biotechs over the past few years. Today you can add Selecta Biosciences to the list of crossover-cash recipients, and pencil the Watertown, MA-based company as a future IPO candidate to boot. Selecta, a developer of nanoparticle technology, has raised a $38 million […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Selecta, Eyeing IPO, Brings Sanofi, Crossovers Aboard For $38M Round

East Coast Biotech Roundup: Vertex, Moderna, Sage, ASCO & More

Memorial Day is just around the corner, and in biotech that doesn’t just mean barbecues; it means the year’s big cancer meeting, the American Society of Clinical Oncology’s (ASCO) annual bash in Chicago, is on tap. There’s still some time before the festivities, however, so don’t fire up those grills just yet. We’re looking back […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Vertex, Moderna, Sage, ASCO & More

Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals

Selecta Biosciences looks to have found two new potential niches for its nanoparticle technology. The Watertown, MA-based company is announcing two deals this morning. First, Selecta said that Sanofi has chosen to license a potential immunotherapy treatment for celiac disease, the allergic disorder that renders people unable to digest gluten. Sanofi got the option as […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals

East Coast Biotech Roundup: Varmus, Bristol, Aerie, Aura & More

Big news in the oncology world this week, with much of the action on the East Coast. The National Cancer Institute’s director is stepping down—and heading back to New York. The first so-called “checkpoint” inhibitor was approved for lung cancer. And one of the biggest biotech deals ever was made around a single cancer drug. […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Varmus, Bristol, Aerie, Aura & More← Older posts